Appointment of New Chairman and Board Changes

PuriCore plc

("PuriCore" or the "Company")

Appointment of New Chairman and Board Changes

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 29 March 2012 - PuriCore (LSE: PURI), the water-based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announces the appointment of a new Chairman and other board changes.

After 10 years as Chairman and in line with corporate governance best practice, Chris Wightman is stepping down from the Board. Chris will remain with the Company to focus principally on the development of PuriCore's technology into new and existing markets. Michael Ashton who was appointed as an additional independent Non-Executive Director on 1 February 2012 is being appointed as Non-Executive Chairman. James Walsh, PhD who was an independent Non-Executive Director of the Company between September 2006 and July 2010 is rejoining the Board as an additional independent Non-Executive Director and will assume the role of Senior Independent Director.

All of the above changes are to take place with immediate effect.

James Walsh has 25 years general management experience in the healthcare industry with particular experience in diagnostics. He is an Executive Director and Chief Scientific Officer of Trinity Biotech plc, an Irish diagnostics company quoted on NASDAQ. Dr. Walsh is Chairman of Biosensia Limited and GenCell Biosystems Limited, both early stage lifescience companies. He also holds Non-Executive Director positions with a number of early stage biotechnology companies.

Dr. Walsh is a graduate of the National University of Ireland and holds a Doctorate in Inorganic Chemistry and Post-Doctorate qualifications in Immunochemistry.

The Company confirms that there is no additional information about Dr. Walsh requiring disclosure under paragraph 9.6.13(1) to (6) of the Listing Rules of the UK Listing Authority.

Michael Ashton, Non-Executive Chairman of PuriCore, commented:

"I am delighted to accept the role of Chairman of PuriCore and look forward to working with senior management and engaging with our stakeholders to continue to develop the Group's full potential. I welcome the addition of James Walsh's broad healthcare experience back to our Board and also look forward to working with him. I thank Chris Wightman for his significant contribution as Chairman over the last ten years and look forward to working with him in his new role."

Enquiries:

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.